Science & Enterprise subscription

Please share Science & Enterprise

RSS
Follow by Email
Facebook
Facebook
Google+
Twitter
Visit Us
LinkedIn
INSTAGRAM

Update – Verily Suspends Glucose-Sensing Contact Lens Project

Smart contact lenses

An initiative developing a contact lens that measures blood glucose levels in tear fluid is now on hold, according to Verily Life Sciences, a division of Alphabet, the parent company of Google. . . . → Read More: Update – Verily Suspends Glucose-Sensing Contact Lens Project

Gene Silencing Technology Licensed in $3.7B Deal

RNA strand illustration

Dicerna Pharmaceuticals, developing treatments for disease that silence genes by interfering with their RNA instructions, is licensing its technology to drug maker Eli Lilly and Co . . . → Read More: Gene Silencing Technology Licensed in $3.7B Deal

BASF Licensing Precise Crispr Editing from Broad Institute

Crispr-Cas9 illustration

The global chemical company BASF is licensing a more precise form of genome editing from the Broad Institute, a genetics research center affiliated with Harvard University and MIT. . . . → Read More: BASF Licensing Precise Crispr Editing from Broad Institute

Licensing Deal for Bioinks in 3-D Printed Transplant Lungs

Human lungs illustration

A company in Maryland developing alternatives to human organ transplants is licensing a technology to help create 3-D printed lungs for transplantation with bioinks derived from tobacco plants. . . . → Read More: Licensing Deal for Bioinks in 3-D Printed Transplant Lungs

Harvard Spin-Off, AbbVie Partner on Fibrosis Treatments

Handshake

Drug maker AbbVie and biotechnology company Morphic Therapeutic are collaborating on new treatments for fibrosis based on Morphic’s technology blocking proteins that promote fibrosis. . . . → Read More: Harvard Spin-Off, AbbVie Partner on Fibrosis Treatments

Start-Up Developing Immunometabolism Therapies, Gains $30M Funding

T-cells illustration

A start-up enterprise founded by medical researchers in the U.S. and Europe is developing treatments for cancer and autoimmune disorders that change chemical reactions in immune system cells. . . . → Read More: Start-Up Developing Immunometabolism Therapies, Gains $30M Funding

Biotech in $3.7B Licensing Deal for Hepatitis-B

Hepatitis-B virus

A biotechnology company developing therapies that silence the actions of disease-causing genes is licensing its treatment program for hepatitis-B to Janssen Pharmaceuticals. . . . → Read More: Biotech in $3.7B Licensing Deal for Hepatitis-B

Virtual Reality Therapy Company Gains $5.1M in Early Funds

Scene from VR program

A company in the U.K. developing automated treatments for phobias using immersive virtual reality is raising £3.2 million ($US 5.1 million) in its first venture funding round. . . . → Read More: Virtual Reality Therapy Company Gains $5.1M in Early Funds

Gilead Gains Genome-Editing Hepatitis B Therapy

Hepatitis-B virus

Biopharmaceutical company Gilead Sciences is acquiring a genome-editing technology for treating hepatitis-B, a viral disease affecting the liver. . . . → Read More: Gilead Gains Genome-Editing Hepatitis B Therapy

Appeals Court Backs Broad Institute in Crispr Case

Crispr genome edits illustration

A U.S. appeals court supported the Broad Institute’s claims it invented a separate Crispr technology from University of California, affirming a previous U.S. patent office ruling. . . . → Read More: Appeals Court Backs Broad Institute in Crispr Case